As the 340B Drug Pricing Program faces significant regulatory and operational changes, covered entities are preparing for the potential impact of a new rebate-based model. In an episode of 340B Pulse, a podcast by NorthArc Health, Jesse Dresser joined host Muhammad Atif to discuss the proposed 340B rebate model, the legal challenges surrounding its implementation, and what these developments could mean for hospitals and other covered entities.
Jesse discusses the uncertainty surrounding the proposed January 2027 implementation, including potential legal obstacles and the financial risks associated with transitioning from upfront 340B discounts to a rebate-based system. The discussion explores how delayed or denied rebates could affect covered entities’ cash flow, create additional administrative burdens, and introduce new compliance considerations. Jesse also addresses the importance of understanding the evolving legal landscape and preparing for potential changes while regulatory and litigation developments continue to unfold.
